Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Market Closed 01-16 16:00:00 EST

4.58

-0.06

-1.29%

盘后4.60

+0.02+0.44%

19:54 EST

High4.82	Low4.57	Vol1.57M
Open4.62	D1 Closing4.64	Amplitude5.39%
Mkt Cap295.73M	Tradable Cap249.21M	Total Shares64.57M
T/O7.34M	T/O Rate2.89%	Tradable Shares54.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.58,"timestamp":1768597200000,"preClose":4.64,"halted":0,"volume":1572883,"hourTrading":{"tag":"盘后","latestPrice":4.6,"preClose":4.58,"latestTime":"19:54 EST","volume":11250,"amount":51977.0266,"timestamp":1768611244020,"change":0.02,"changeRate":0.004367,"amplitude":0},"delay":0,"changeRate":-0.012931034482758537,"floatShares":54411779,"shares":64569967,"eps":-1.75688,"marketStatus":"Market Closed","change":-0.06,"latestTime":"01-16 16:00:00 EST","open":4.62,"high":4.82,"low":4.57,"amount":7344717.941529,"amplitude":0.053879,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.75688,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":4.64,"preHourTrading":{"tag":"盘前","latestPrice":4.61,"preClose":4.64,"latestTime":"09:29 EST","volume":8322,"amount":38328.01125,"timestamp":1768573761060,"change":-0.03,"changeRate":-0.006466,"amplitude":0.030172},"postHourTrading":{"tag":"盘后","latestPrice":4.6,"preClose":4.58,"latestTime":"19:54 EST","volume":11250,"amount":51977.0266,"timestamp":1768611244020,"change":0.02,"changeRate":0.004367,"amplitude":0},"volumeRatio":0.474207008403122,"impliedVol":1.4387,"impliedVolPercentile":0.6081},"requestUrl":"/m/hq/s/IMRX/wiki","defaultTab":"wiki","newsList":[{"id":"2604608919","title":"Immuneering Chief Scientific Officer Brett Matthew Hall Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2604608919","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604608919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:08","pubTimestamp":1768597708,"startTime":"0","endTime":"0","summary":"Brett Matthew Hall, Chief Scientific Officer of Immuneering Corporation, reported the acquisition of Class A Common Shares of Immuneering Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL8N0RsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuneering Chief Scientific Officer Brett Matthew Hall Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","BK4139","IMRX"],"gpt_icon":0},{"id":"2603953322","title":"Top Immuneering Executive Makes Bold Move With Fresh Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2603953322","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603953322?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:03","pubTimestamp":1768529024,"startTime":"0","endTime":"0","summary":"New insider activity at Immuneering ( ($IMRX) ) has taken place on January 15, 2026. Immuneering’s Chief People Officer, Leah R. Neufeld, has boost...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-immuneering-executive-makes-bold-move-with-fresh-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-immuneering-executive-makes-bold-move-with-fresh-stock-purchase-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2603260011","title":"Immuneering Chief People Officer Leah R. Neufeld Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603260011","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603260011?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:06","pubTimestamp":1768482401,"startTime":"0","endTime":"0","summary":"Leah R. Neufeld, Chief People Officer of Immuneering Corporation, reported the acquisition of Class A common shares of Immuneering Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbX0Cz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuneering Chief People Officer Leah R. Neufeld Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2603624985","title":"Immuneering Insider Makes Bold New Bet on Company’s Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2603624985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603624985?lang=en_us&edition=fundamental","pubTime":"2026-01-15 10:02","pubTimestamp":1768442567,"startTime":"0","endTime":"0","summary":"New insider activity at Immuneering ( ($IMRX) ) has taken place on January 14, 2026. Director Peter Feinberg has made a notable move in Immuneering...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/immuneering-insider-makes-bold-new-bet-on-companys-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/immuneering-insider-makes-bold-new-bet-on-companys-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2602394546","title":"Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2602394546","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602394546?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:55","pubTimestamp":1767894915,"startTime":"0","endTime":"0","summary":"After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with mod...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-updated-12-month-data-for-atebimetinib-encouraging-says-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-updated-12-month-data-for-atebimetinib-encouraging-says-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","IMRX","BK4563"],"gpt_icon":0},{"id":"2602999303","title":"Immuneering Down Nearly 40%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2602999303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602999303?lang=en_us&edition=fundamental","pubTime":"2026-01-09 00:56","pubTimestamp":1767891360,"startTime":"0","endTime":"0","summary":"Immuneering Corp. Class A  is currently at $5.02, down $3.31 or 39.74%. --Would be lowest close since Aug. 22, 2025, when it closed at $4.89. --On pace for largest percent decrease since March 14, 2024, when it fell 50.68%. --Down 84.71% from its all-time closing high of $32.84 on Sept. 27, 2021. --Up 151% from 52 weeks ago , when it closed at $2.00. --Up 356.36% from its 52-week closing low of $1.10 on May 7, 2025. --Traded as low as $4.80; lowest intraday level since Aug. 25, 2025, when it hit $4.70. --Down 42.38% at today's intraday low; largest intraday percent decrease since March 14, 2024, when it fell as much as 52.38%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","IMRX","BK4139"],"gpt_icon":0},{"id":"2601013364","title":"Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2601013364","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601013364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:06","pubTimestamp":1767877560,"startTime":"0","endTime":"0","summary":"U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Thursday.Shares of Immuneering Corp  fell sharply in pre-market trading.The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.Immuneering shares dipped 20.7% to $6.61 in pre-market trading.Here are some other stocks moving lower in pre-market trading.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4141","BK4563","BK4588","IMRX","PHAT","BK4539","BK4526","BK4585","BK4139","BK4519","BK4007"],"gpt_icon":1},{"id":"2601350114","title":"Stock Market Today: S&P 500, Dow Jones Futures Decline — AZZ, Northrop Grumman, Immuneering In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2601350114","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601350114?lang=en_us&edition=fundamental","pubTime":"2026-01-08 18:17","pubTimestamp":1767867466,"startTime":"0","endTime":"0","summary":"U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the Nasdaq 100 index ending in green.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/01/49776170/stock-market-today-sp-500-dow-jones-futures-decline-azz-northrop-grumman-immuneering-in-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NOC","SSO","BK4564","LU1064131342.USD","BK4561","MESmain","ESmain","LU2552382132.HKD","BK4550","BK4007","BK4534","LU2552382058.USD","SH","BK4516","SDS","BK4182","BK4532","SPXU",".SPX","IVV","BK4593","LU1430594728.SGD","LU1988902786.USD","BK4585","BK4139","BK4169","UPRO","LU2264538146.SGD","IMRX","BK4588","BK4603","BK4504","OEX","BK4187","BK4559","SPY","LU2552382215.SGD","BK4581","AZZ","BK4563","LU1585245621.USD","BK4086","OEF"],"gpt_icon":1},{"id":"1189971146","title":"Immuneering Corp (IMRX.US) Plunges 21% After-Hours Despite Pancreatic Cancer Therapy Outperforming Standard of Care, Lagging Behind Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=1189971146","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189971146?lang=en_us&edition=fundamental","pubTime":"2026-01-08 09:20","pubTimestamp":1767835223,"startTime":"0","endTime":"0","summary":"Biotechnology firm Immuneering Corp. (IMRX.US) saw its shares plummet approximately 21% in Wednesday's after-hours trading following the release of Phase 2a clinical trial results for atebimetinib as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"2601338604","title":"Immuneering Reports 64% 12-Month Overall Survival in Phase 2a Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601338604","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601338604?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:00","pubTimestamp":1767819622,"startTime":"0","endTime":"0","summary":"Immuneering Corporation announced positive updated overall survival and safety data from its ongoing Phase 2a clinical trial of atebimetinib  in combination with modified gemcitabine/nab-paclitaxel  for first-line pancreatic cancer patients. With over 13 months median follow-up, the 12-month overall survival rate was reported at 64%, nearly double that of the benchmark from the pivotal study of the standard of care. Median overall survival has not yet been reached as of the data cutoff. Immuneering plans to report updated survival data from over 50 patients treated with atebimetinib + mGnP in the first half of 2026, and updated circulating tumor DNA data in the second quarter of 2026. The company anticipates dosing the first patient in its pivotal Phase 3 MAPKeeper 301 trial in mid-2026. Results from the Phase 2a trial have already been presented, and additional data will be presented at future scientific meetings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL1FsTCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4539","SG9999014021.USD","IMRX","BK4563","LU0314104364.USD","BK4585","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2601097386","title":"Immuneering Announces Exceptional 64% Overall Survival at 12 Months in First-Line Pancreatic Cancer Patients Treated With Atebimetinib + Mgnp","url":"https://stock-news.laohu8.com/highlight/detail?id=2601097386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601097386?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:00","pubTimestamp":1767819600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2PGS1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","BK4563","IMRX"],"gpt_icon":0},{"id":"2601013386","title":"Immuneering Corp - to Dose First Patient in Phase 3 Trial Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601013386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601013386?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:00","pubTimestamp":1767819600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUA2PGS1V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2594824123","title":"Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594824123","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594824123?lang=en_us&edition=fundamental","pubTime":"2025-12-27 22:09","pubTimestamp":1766844576,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Immuneering's stock price is sensitive to their trading...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/institutional-investors-control-36-of-immuneering-corporatio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imrx/immuneering/news/institutional-investors-control-36-of-immuneering-corporatio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4563","TSYW.SI","TQQQ",".IXIC","PSQ","IMRX","QID","USJW.SI","BK4139","USAW.SI","QLD","SQQQ","NVIW.SI","MNQmain","BK4539","NQmain"],"gpt_icon":1},{"id":"2593490006","title":"BRIEF-Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnP","url":"https://stock-news.laohu8.com/highlight/detail?id=2593490006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593490006?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495529,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneering To Announce 12-Month Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + mGnPDec 23 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA2VXW2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"2593406490","title":"Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593406490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593406490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494820,"startTime":"0","endTime":"0","summary":"Immuneering Corporation announced that it will present 12-month overall survival data from its ongoing Phase 2a clinical trial of atebimetinib in combination with modified Gemcitabine/nab-paclitaxel  in first-line pancreatic cancer patients. The results will be provided during a conference call and live webcast scheduled for January 7, 2026. The company stated that the webcast will be available in the Investor Relations section of Immuneering's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire  on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8sHp1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","SG9999014039.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","LU2210150020.SGD","IMRX","LU2095319765.USD","IE00BGHQF748.EUR","BK4539","IE00BKPKM429.USD","SG9999014021.USD","BK4139","BK4563"],"gpt_icon":0},{"id":"2593249012","title":"Immuneering to Announce 12-Month Overall Survival Data From Phase 2a Clinical Trial of Atebimetinib + Mgnp in First-Line Pancreatic Cancer Patients on January 7, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593249012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593249012?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:00","pubTimestamp":1766494803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA2VXW2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4563","IMRX"],"gpt_icon":0},{"id":"2592943915","title":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943915","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943915?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:08","pubTimestamp":1766005722,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib TrialDec 17 (Reuters) - Immuneering Corp IMRX.O:IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4139","BK4539"],"gpt_icon":0},{"id":"2592943674","title":"Immuneering: Expects to Share Topline Results From Trial in Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943674?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005550,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"2592943671","title":"Immuneering Expects to Dose First Patient in Global Phase 3 Registrational Trial, Mapkeeper 301, in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943671?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005550,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"2592943942","title":"Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943942?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005500,"startTime":"0","endTime":"0","summary":"– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Ov","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207312/0/en/Immuneering-Advances-Towards-Dosing-First-Patient-in-Phase-3-Atebimetinib-Trial-for-First-Line-Metastatic-Pancreatic-Cancer-Patients-Securing-Alignment-with-FDA-and-EMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4081","BK4539","EMA","IMRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":-0.1673},{"period":"3month","weight":-0.1792},{"period":"6month","weight":0.109},{"period":"1year","weight":1.3367},{"period":"ytd","weight":-0.304}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.228229},{"month":2,"riseRate":0.5,"avgChangeRate":-0.044801},{"month":3,"riseRate":0.25,"avgChangeRate":0.059789},{"month":4,"riseRate":0.25,"avgChangeRate":-0.2067},{"month":5,"riseRate":0.25,"avgChangeRate":0.005771},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}